Frequently Asked Questions

  • A typical ETO validation (including protocol development and approval, validation runs, and sterility testing commonly takes 90 - 120 days for a device with an existing sterilization cycle. Timelines also depend on test sample availability, regulatory approvals, and chamber availability at the sterilizer.

  • Choose ETO when:

    • The product or packaging is heat- or radiation-sensitive (e.g., many polymers, electronics, packed kits).

    • You need sterilization with good penetration for complex assemblies.

    Choose Gamma or e-beam when:

    • You need fast throughput and no chemical residues.

    • The product and packaging are radiation-tolerant (metals, some polymers).

      Tradeoffs: ETO requires aeration time and chemical residue controls and has complex regulatory documentation; irradiation avoids residues but can cause polymer degradation or packaging discoloration. Selection should be based on material compatibility testing, product design, throughput needs, cost, and regulatory expectations.

  • Material choice depends on:

    1. Biocompatibility (ISO 10993 requirements).

    2. Mechanical needs (flexibility, kink resistance, tensile strength, burst pressure).

    3. Chemical compatibility (with drugs, cleaning agents, adhesives, etc).

    4. Sterilization method (ETO, gamma, autoclave)—each has different effects on materials.

      Common choices: medical-grade PVC, TPE, silicone, PTFE, HDPE/LDPE films, and multilayer laminates. Always run extractables/leachables and aging/sterilization compatibility tests early in development and document material certificates and testing for regulatory submissions.

  • For a new product expect several additional months to complete design transfer, process validation (IQ/OQ/PQ), first-article production, packaging, and shelf-life studies (if needed), sterility validations, and full documentation. Simpler devices or those leveraging existing validated processes can be faster; novel designs, new materials, or new sterilization routes will push timelines toward the longer end.

  • Advantages of Mexico:

    • Lower labor and facility costs compared to many U.S. locations.

    • Strong manufacturing clusters for medical devices in northern Mexico with an experienced workforce.
      Considerations: regulatory compliance, quality controls, and supplier due diligence are equally important — choose partners with strong QMS and proven operations and import/ export experience.

  • IQ/OQ/PQ are the core elements of equipment or process qualification:

    • IQ — Installation Qualification: verifies equipment was installed correctly and per manufacturer/specification (utilities, environmental requirements, calibration).

    • OQ — Operational Qualification: demonstrates equipment or process operates across the intended ranges and meets the defined performance parameters (controls, alarms, limits).

    • PQ — Performance Qualification: proves the equipment/process can consistently produce a product that meets specifications under routine production conditions (typically includes process validation lots and performance metrics).
      Together they form a documented evidence trail that a system is fit for intended use and are required parts of a robust QMS and regulatory submissions.

  • A Single Lot Release (SLR) / Batch Release is the formal approval that a specific sterilization lot (or batch) has met all defined acceptance criteria and is released for distribution. It typically includes:

    • Review of sterilizer run records and cycle parameters.

    • Biological indicator and viability test results.

    • Residual ETO or EO-byproduct testing (if required).

    • Packaging and visual inspection records.

     An authorized Quality Representative signs the release after confirming traceability, test acceptance, and documentation completeness.

  • Key selection criteria:

    • Regulatory pedigree: ISO 13485 certification, experience with FDA/QSR, and international regs relevant to your market.

    • Technical fit: experience with your product class (materials, processes, sterilization), tooling, and cleanroom capabilities.

    • Cultural/communication fit: responsiveness, transparency, and project management.
      Request audits, technical references, and a sample validation report.

    • Quality systems & documentation: strong CAPA, change control, supplier management, device history record capability.

    • Capacity & lead times: ability to scale and meet seasonal demand.

    • Supply chain location & cost: proximity to key markets or components.

  • A line transfer validation (transferring production to a new facility or line) typically takes 6 months to a year. Activities include installation qualification (IQ), operational qualification (OQ), process capability assessments, first-article inspections, sterility/sterilization validations if applicable, and master documentation updates. Complexity, regulatory submission requirements, supplier requalifications, and tooling lead times can extend this timeline.

  • Vertical integration delivers several advantages:

    • Reduced lead times and cost by eliminating intermediate supplier mark ups Better quality control — single QMS and traceability across bag, fill, and sterilizationsteps.

    • Lower logistics risk and cost (fewer transport steps and suppliers).

    • Faster troubleshooting and change implementation (one partner owns the end-to-end process).

    • Improved supply security during demand spikes or disruptions.
      This is particularly valuable for single-use systems, drug-device combinations, or products where fill/closure integrity and sterile barrier performance are critical.

  • Compared to other low-cost regions, Mexico offers:

    • Closer logistics to U.S. customers — faster shipping, lower freight cost, and easier returns.

    • Reduced geopolitical and IP risk for many U.S. companies versus some overseas locations.

    • Time-zone alignment and cultural/business proximity improve collaboration and responsiveness.

    • USMCA framework vs. different trade regimes elsewhere, which can simplify cross-border regulatory and tariff issues.
      Costa Rica and other LATAM countries may offer competitive labor and good regulatory ecosystems (and are also near-shore), while China gives scale and cost advantages for high-volume commodity components. The best choice depends on product complexity, IP sensitivity, logistics priorities, and supplier maturity.